Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Dynamics Special Purpose Corp. completed combination with Senti Biosciences
We advised Dynamics Special Purpose Corp. on this transaction
InSilico Medicine $60 million Series D financing
We are advising InSilico Medicine in connection with its $60 million Series D financing
Astorg acquisition of OPEN Health
We are advising Astorg on the transaction
GSK $3.3 billion acquisition of Affinivax
We are advising GSK on the acquisition
Laekna Therapeutics $61 million Series D financing
We are advising Laekna Therapeutics in connection with its Series D financing
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Anthem $1.3 billion senior notes offering
The investment-grade notes are due 2032 and 2052
Deciphera Pharmaceuticals $172.5 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
HilleVax $200 million IPO
The shares are listed on the Nasdaq Global Select Market
Acutus Medical sale of its left-heart access portfolio products
We are advising Acutus Medical on the transaction